Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers
CDK2, CDK4, CDK2/4/6 Drugs Now In Early Trials
Pfizer is looking to address breast cancer resistant to Ibrance and other CDK4/6 inhibitors, but sees potential paths to earlier lines of treatment and additional tumors.
